NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

市場焦點:痤瘡

Market Spotlight: Acne

出版商 Datamonitor Healthcare 商品編碼 997347
出版日期 內容資訊 英文 46 Pages
商品交期: 最快1-2個工作天內
價格
市場焦點:痤瘡 Market Spotlight: Acne
出版日期: 2021年03月15日內容資訊: 英文 46 Pages
簡介

據估計,2019年全球痤瘡病例數約為6.125億,預計到2028年將增至6.586億。

在痤瘡領域中批准的藥物著重於各種目標。這些藥物通過口服和局部途徑給藥。

在痤瘡的積極臨床開發中,大多數由行業贊助的藥物都處於II期階段,只有一種產品處於NDA/BLA階段。

這份市場焦點報告包括主要的非處方藥和管線化痤瘡藥物,近期事件和分析師意見,臨床試驗,即將到來的監管事件,成功的潛力以及10年的疾病流行率,它概述了痤瘡。市場,包括費率預測,許可和收購交易以及針對特定藥物的收入預測。

目錄

內容

概述

要點

疾病背景

治療

  • 局部治療
  • 全身療法
  • 物理治療

流行病學

非處方藥

管道醫學

最近發生的事件和分析師的觀點

  • 痤瘡的VB1953(2020年6月16日)
  • 痤瘡的DMT310(2020年6月10日)
  • 痤瘡的FCD105(2020年6月2日)
  • Twyneo祛痘(2019年12月30日)

即將發生的重大事件

重大監管事件

  • 卡西歐(Carsiopea)的Winlevi為痤瘡市場帶來了新藥類

成功的可能性

許可和資產收購交易

  • GSK與Eligo簽署皮膚病學合同
  • 歐萊雅的微生物菌群探索導致與Micreo達成了下一代抗菌藥物的協議
  • Paratek與Almirall合作,將痤瘡藥帶入中國

收入機會

臨床試驗情況

  • 按狀態贊助
  • 分階段贊助
  • 最近事件

參考

  • 處方信息

附錄

數字列表

表列表

目錄
Product Code: DMKC0181187

This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2019, there were approximately 612.5 million prevalent cases of acne worldwide, and forecasts that number to increase to 658.6 million prevalent cases by 2028.

Approved drugs in the acne space focus on a wide variety of targets. These drugs are administered via the oral and topical routes.

The majority of industry-sponsored drugs in active clinical development for acne are in Phase II, with just a single product in the NDA/BLA stage.

Therapies in development for acne focus on a wide variety of targets. The majority of the pipeline drugs are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.

The only high-impact upcoming event for drugs in the acne space is an expected PDUFA date for Twyneo. The overall likelihood of approval of a Phase I dermatology-general asset is 20.2%, and the average probability a drug advances from Phase III is 68%. Drugs, on average, take 8.8 years from Phase I to approval in the dermatology-general space, as well as in the overall dermatology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for acne have been in the late phases of development, with 52% of trials in Phase III-IV, and 48% in Phase I-II.

The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.

GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for acne, followed by AbbVie.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Topical therapy
  • Systemic therapy
  • Physical treatments

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • VB 1953 for Acne (June 16, 2020)
  • DMT310 for Acne (June 10, 2020)
  • FCD105 for Acne (June 2, 2020)
  • Twyneo for Acne (December 30, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Cassiopea's Winlevi Brings New Drug Class To Acne Market

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • GSK Inks Dermatology Pact With Eligo
  • L'Oreal's Microbiome Explorations Lead To Micreos Deal For Next-Gen Antibacterial
  • Paratek, Almirall Partner To Bring Acne Medicine To China

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of acne, 2019-28
  • Figure 2: Overview of pipeline drugs for acne in the US
  • Figure 3: Pipeline drugs for acne, by company
  • Figure 4: Pipeline drugs for acne, by drug type
  • Figure 5: Pipeline drugs for acne, by classification
  • Figure 6: VB 1953 for Acne (June 16, 2020): Phase II - Facial Acne Vulgaris
  • Figure 7: DMT310 for Acne (June 10, 2020): Phase IIb - 003
  • Figure 8: FCD105 for Acne (June 2, 2020): Phase II - Acne Vulgaris
  • Figure 9: Twyneo for Acne (December 30, 2019): Phase III - SGT-65-04, Phase III - SGT-65-05
  • Figure 10: Key upcoming events in acne
  • Figure 11: Probability of success in the dermatology-general pipeline
  • Figure 12: Clinical trials in acne
  • Figure 13: Top 10 drugs for clinical trials in acne
  • Figure 14: Top 10 companies for clinical trials in acne
  • Figure 15: Trial locations in acne
  • Figure 16: Acne trials status
  • Figure 17: Acne trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of acne, 2019-28
  • Table 2: Marketed drugs for acne
  • Table 3: Pipeline drugs for acne in the US
  • Table 4: VB 1953 for Acne (June 16, 2020)
  • Table 5: DMT310 for Acne (June 10, 2020)
  • Table 6: FCD105 for Acne (June 2, 2020)
  • Table 7: Twyneo for Acne (December 30, 2019)
  • Table 8: Historical global sales, by drug ($m), 2015-19
  • Table 9: Forecasted global sales, by drug ($m), 2021-25